Clinical Trials Directory

Trials / Unknown

UnknownNCT04653961

Evaluation of a Decision Support System for People With Diabetes Who Use Multiple Daily Insulin Injections- Feasibility and Proof of Concept Studies

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
48 (estimated)
Sponsor
Rabin Medical Center · Academic / Other
Sex
All
Age
14 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The study comprises of two segments: a feasibility segment and a Proof of Concept segment. The study is open label, prospective study that will include up to 72 subjects in segment 1 and up to 40 subjects in segment 2. Participants are people with Type 1 or type 2 Diabetes treated with Multiple Daily Injections ( MDI) and Self Monitoring of Blood Glucose (SMBG) or intermittent Continuous Glucose Monitoring (CGM). The study will include screening, a 2-4-week run-in period and 10-12 weeks intervention period. Subjects will be asked to record their insulin delivery during basal/bolus insulin treatment (using dedicated apps ) and their daily activities (meals, physical activity etc.) using electronic log (implemented on Dedicated Apps), for a total period of 12-16 weeks. The goal of this study is to evaluate the safety of a decision support system for adjustment of insulin treatment plan for people with diabetes using multiple daily injections and monitoring glucose by SMBG or intermittent CGM

Conditions

Interventions

TypeNameDescription
DEVICEDreaMed Advisor Pro DSS-MDI algorithmThe DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).

Timeline

Start date
2020-06-01
Primary completion
2025-10-01
Completion
2025-10-01
First posted
2020-12-04
Last updated
2024-03-27

Locations

2 sites across 1 country: Israel

Source: ClinicalTrials.gov record NCT04653961. Inclusion in this directory is not an endorsement.